The landscape of chromosomal instability in uterine leiomyosarcoma.

S Sara Moufarrij (Memorial Sloan Kettering Cancer Center, New York, NY) Q Qin Zhou A Alexia Iasonos S Sana Hatoum (Memorial Sloan Kettering Cancer Center, New York, NY) M Martee Leigh Hensley (Memorial Sloan Kettering Cancer Center, New York, NY) S Sminu Bose (Memorial Sloan Kettering Cancer Center, New York, NY) S Sarah Chiang (Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) A Amir Momeni-Boroujeni (Memorial Sloan Kettering Cancer Center, New York, NY)

Abstract

5607 Background: Uterine leiomyosarcoma (uLMS) has heterogeneous clinical presentations and outcomes. Although most uLMSs are associated with chromosomal instability, limited data exist on chromosomal instability patterns and their association with clinical outcomes. We sought to examine the chromosomal and genomic landscape of uLMSs and their association with survival outcomes. Methods: We identified 162 patients with uLMS who underwent matched tumor-normal next-generation sequencing at our institution between 2007 and 2024. Allele-specific copy number analysis was performed using the FACETS algorithm with genome-wide summary data as well as focal copy number data extracted and compared with clinical variables and survival outcomes. Appropriate statistical analyses were performed. Results: The median age at diagnosis was 55 years (range, 30-92). The uLMS in the cohort predominantly had conventional spindle cell morphology (n=122/162, 75%). At the time of diagnosis, 42% presented as FIGO stage I disease (68/162) followed by FIGO stage IV disease (60/162, 37%). ER expression data was available for 155 cases, with the majority of cases being ER positive (106/155, 68%). PR expression data was available for 145 cases, with most of the tumors expressing PR (87/145, 60%). The most common alterations in the cohort were TP53 (117, 72%), RB1 (78, 48%), ATRX (62, 38%), and PTEN (31, 19%). FACETS analysis showed that 15% of tumors (25/162) were hypoploid and 12% had whole-genome duplication (20/162). The median telomeric size was 50.1 Mb (interquartile range [IQR]: 40-59.3). The median number of telomeric allele imbalances was 6 (IQR: 3-9). The median fraction of genome with loss of heterozygosity was 0.28 (IQR: 0.14-10.5). Centromeric allele imbalance, whole-genome duplication, and fraction of copy number altered were associated with ER expression (adjusted P=0.025, 0.015, and 0.002, respectively). Multivariate survival analysis demonstrated that hypoploidy (hazard ratio: 3.3) and copy number alterations in PIK3CD (hazard ratio: 1.82) were associated with worse overall survival (P<0.001 for both). Conclusions: Although most uLMSs are caused by underlying chromosomal instability, the patterns in these tumors are variable, with some of the chromosomal instability configurations having prognostic implications. Further studies are needed to better understand the role of chromosomal instability in the stratification of the disease.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 5607-5607
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (8)

S

Sara Moufarrij

Memorial Sloan Kettering Cancer Center, New York, NY

Q

Qin Zhou

A

Alexia Iasonos

S

Sana Hatoum

Memorial Sloan Kettering Cancer Center, New York, NY

M

Martee Leigh Hensley

Memorial Sloan Kettering Cancer Center, New York, NY

S

Sminu Bose

Memorial Sloan Kettering Cancer Center, New York, NY

S

Sarah Chiang

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

A

Amir Momeni-Boroujeni

Memorial Sloan Kettering Cancer Center, New York, NY